Skip to main content
Equibles
PDEX logo

PDEX · Pro Dex Inc · Metrics

Track PDEX — free

Use PDEX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PDEX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$62.19 -0.19 (-0.30%)
Russell 2000 member Rebalance outlook locked
Market Cap
$199.82M
Shares
3.20M
Volume · Oct 23 49.46K Avg daily vol (3M) 67.12K

PDEX metrics

108 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$62.38
Market cap
$199.82M

Price action

20 metrics
Price change (1W)
+3.9%
Price change (30D)
-13.9%
Price change (3M)
+14.1%
Price change (6M)
+22.4%
Price change (YTD)
+62.1%
Price change (1Y)
+136.6%
Trailing year
Price change (5Y)
+145.3%
52-week high
$73.41
52-week low
$26.36
Change from 52-week high
-15.0%
Change from 52-week low
+136.6%
Annualized volatility
58.4%
Annualized volatility (3M)
63.2%
Beta
1.2
RSI (14D)
47.2
Price vs SMA 50
-4.7%
Price vs SMA 200
+11.5%
Avg volume (3M)
67,083
Relative volume
0.3
Average dollar volume
$4.36M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
3.20M

Valuation

12 metrics
P / E (TTM)
15.1
Trailing earnings · reciprocal yield 6.6%
PEG ratio
0.1
EV / revenue
2.6×
reciprocal yield 38.4%
EV / EBITDA
14.1×
reciprocal yield 7.1%
EV / EBIT
15.6×
reciprocal yield 6.4%
P / sales
2.5×
reciprocal yield 40.0%
P / book
4.1
reciprocal yield 24.6%
FCF yield
3.5%
TTM · current market cap
Buyback yield
—
P / FCF
28.7
reciprocal yield 3.5%
P / operating cash flow
26.8
reciprocal yield 3.7%
Earnings yield
7.0%

Historical valuation

8 metrics
P / E historical average (3Y)
15.2×
reciprocal yield 6.6%
P / E historical average (5Y)
16.0×
reciprocal yield 6.3%
EV / revenue historical average (3Y)
2.0×
reciprocal yield 49.9%
EV / revenue historical average (5Y)
1.9×
reciprocal yield 51.7%
EV / EBIT historical average (3Y)
13.2×
reciprocal yield 7.6%
EV / EBIT historical average (5Y)
14.0×
reciprocal yield 7.1%
EV / EBITDA historical average (3Y)
11.6×
reciprocal yield 8.6%
EV / EBITDA historical average (5Y)
12.8×
reciprocal yield 7.8%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
31.4%
Operating margin
16.8%
Trailing 12 months
Net margin
17.6%
Gross profit (TTM)
$24.34M
Operating profit (TTM)
$12.99M
Net income (TTM)
$13.66M
Trailing 12 months
Diluted EPS (TTM)
$4.12
FCF margin
8.7%
Effective tax rate
24.2%

Per share

11 metrics
Revenue per diluted share (TTM)
$23.38
Gross profit per diluted share (TTM)
$7.34
Operating profit per diluted share (TTM)
$3.92
EBITDA per diluted share (TTM)
$4.34
Net income per diluted share (TTM)
$4.12
Operating cash flow per diluted share (TTM)
$2.19
Free cash flow per diluted share (TTM)
$2.05
Capital expenditures per diluted share (TTM)
$0.15
R&D per diluted share (TTM)
$1.01
Stock compensation per diluted share (TTM)
$0.21
Book value per share
$14.95

Growth

11 metrics
Revenue growth YoY
+16.6%
Year over year
Net income growth YoY
+138.7%
Revenue (TTM)
$77.55M
Trailing 12 months
EPS growth YoY
+160.6%
Shares change YoY
-2.0%
Year over year · fewer shares
Revenue CAGR (3Y)
+18.9%
Revenue CAGR (5Y)
+15.3%
EPS CAGR (3Y)
+28.3%
EPS CAGR (5Y)
+21.3%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
28.7%
Return on assets
18.3%
Debt / equity
0.4
Current ratio
4.1
EBITDA (TTM)
$14.38M
Free cash flow (TTM)
$6.76M
Quick ratio
2.4
Interest coverage
16.0
Net debt / EBITDA
0.6
Return on invested capital
17.7%
Trailing 12 months
Net cash
−$8.17M
Latest balance sheet
Cash & equivalents
$8.19M
Total assets
$74.51M
Total debt
$17.51M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$7.24M
Capital expenditures (TTM)
$483,000
R&D (TTM)
$3.35M
SG&A (TTM)
—
Stock compensation (TTM)
$688,000
R&D / revenue
4.3%
Stock compensation / revenue
0.9%

Ownership (13F)

9 metrics
13F filers
66
13F filer change QoQ
+8
Institutional ownership
22.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
6.2%
Private-fund adviser ownership
5.1%
Active holders' share change QoQ
+12.7%
Holder tenure
11.4
Price vs estimated holder cost
+33.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.9%

Short interest

3 metrics
Short interest
6.2%
Latest settlement · 2.9 days to cover
Days to cover
2.9d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.35M
Insider-sentiment score
40 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 788920 CUSIP 74265M205 13F (30d) 10 filings 10 filers Visit website Investor relations